| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Pathology and Laboratory Medicine*
and Medicine,
Mount Sinai Hospital,
University of Toronto, Toronto, Ontario, Canada; and the Edison
Biotechnology Institute and Department of Biomedical
Sciences,
College of Osteopathic Medicine,
Ohio University, Athens, Ohio
Growth hormone (GH) modulates the hypothalamic release of somatostatin and GH-releasing hormone; however, there has been no evidence of GH autoregulation on the pituitary somatotroph. To determine the effects of GH on its own regulation, we examined the pituitaries of giant transgenic mice expressing a GH agonist (E117L), dwarf transgenic mice expressing a GH antagonist (G119K), and dwarf mice devoid of the GH receptor/binding protein (GHR/BP). In the E117L transgenic mice, the number and distribution of pituitary GH-immunoreactive cells were unchanged from nontransgenic littermate controls; an ultrastructural examination revealed typical, densely granulated somatotrophs. In contrast, the pituitaries of the G119K mice contained both moderately granulated somatotrophs and a sparsely granulated (SG) population with well-developed synthetic organelles and a distinct juxtanuclear globular GH-staining pattern. GHR/BP-deficient mice exhibited a marked reduction in the intensity of cytoplasmic GH immunoreactivity; however, prominent GH staining in the juxtanuclear Golgi was seen. GH-immunoreactive cells were increased in number, and the reticulin network pattern was distorted; stains for proliferating cell nuclear antigen confirmed mild hyperplasia. Electron microscopy showed that the somatotrophs were hyperactive SG cells with prominent endoplasmic reticulum membranes, large Golgi complexes, and numerous mitochondria. These findings are consistent with synthetic and secretory hyperactivity in pituitary somatotrophs due to the reduced GH feedback regulation. The changes are most striking in animals that are devoid of GHR/BP and less marked in animals expressing a GH antagonist; both models had reduced insulin-like growth factor-I levels, but the more dramatic change in the GHR/BP animals can be explained by abrogated GH signaling. This represents the first evidence of direct GH feedback inhibition on pituitary somatotrophs, which may have implications for the use of GH analogs in different clinical settings.
This article has been cited by other articles:
 |
|
 |
|
  S. L. Asa, R. DiGiovanni, J. Jiang, M. L. Ward, K. Loesch, S. Yamada, T. Sano, K. Yoshimoto, S. J. Frank, and S. Ezzat A Growth Hormone Receptor Mutation Impairs Growth Hormone Autofeedback Signaling in Pituitary Tumors Cancer Res., August 1, 2007; 67(15): 7505 - 7511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ezzat, R. Mader, S. Fischer, S. Yu, C. Ackerley, and S. L. Asa An essential role for the hematopoietic transcription factor Ikaros in hypothalamic-pituitary-mediated somatic growth PNAS, February 14, 2006; 103(7): 2214 - 2219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhou, W. K. W. Ko, W. K. K. Ho, S. S. Stojilkovic, and A. O. L. Wong Novel Aspects of Growth Hormone (GH) Autoregulation: GH-Induced GH Gene Expression in Grass Carp Pituitary Cells through Autocrine/Paracrine Mechanisms Endocrinology, October 1, 2004; 145(10): 4615 - 4628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Cingel-Ristic, J. W. van Neck, J. Frystyk, S. L. S. Drop, and A. Flyvbjerg Administration of Human Insulin-Like Growth Factor-Binding Protein-1 Increases Circulating Levels of Growth Hormone in Mice Endocrinology, September 1, 2004; 145(9): 4401 - 4407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Iida, J. P. Del Rincon, D.-S. Kim, E. Itoh, R. Nass, K. T. Coschigano, J. J. Kopchick, and M. O. Thorner Tissue-Specific Regulation of Growth Hormone (GH) Receptor and Insulin-Like Growth Factor-I Gene Expression in the Pituitary and Liver of GH-Deficient (lit/lit) Mice and Transgenic Mice that Overexpress Bovine GH (bGH) or a bGH Antagonist Endocrinology, April 1, 2004; 145(4): 1564 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ezzat, S. Yu, and S. L. Asa Ikaros Isoforms in Human Pituitary Tumors: Distinct Localization, Histone Acetylation, and Activation of the 5' Fibroblast Growth Factor Receptor-4 Promoter Am. J. Pathol., September 1, 2003; 163(3): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Liu, L. Robillard, B. Banihashemi, and P. R. Albert Growth Hormone-induced Diacylglycerol and Ceramide Formation via Galpha i3 and Gbeta gamma in GH4 Pituitary Cells. POTENTIATION BY DOPAMINE-D2 RECEPTOR ACTIVATION J. Biol. Chem., December 6, 2002; 277(50): 48427 - 48433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Brubaker, D. J. Drucker, S. L. Asa, C. Swallow, M. Redston, and G. R. Greenberg Prolonged Gastrointestinal Transit in a Patient with a Glucagon-Like Peptide (GLP)-1- and -2-Producing Neuroendocrine Tumor J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3078 - 3083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Greenhalgh, P. Bertolino, S. L. Asa, D. Metcalf, J. E. Corbin, T. E. Adams, H. W. Davey, N. A. Nicola, D. J. Hilton, and W. S. Alexander Growth Enhancement in Suppressor of Cytokine Signaling 2 (SOCS-2)-Deficient Mice Is Dependent on Signal Transducer and Activator of Transcription 5b (STAT5b) Mol. Endocrinol., June 1, 2002; 16(6): 1394 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yu, S. L. Asa, and S. Ezzat Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary Mol. Endocrinol., May 1, 2002; 16(5): 1069 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Kineman, L. T. Teixeira, G. V. Amargo, K. T. Coschigano, J. J. Kopchick, and L. A. Frohman The Effect of GHRH on Somatotrope Hyperplasia and Tumor Formation in the Presence and Absence of GH Signaling Endocrinology, September 1, 2001; 142(9): 3764 - 3773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-d. Peng, S. Park, M. R. Gadelha, K. T. Coschigano, J. J. Kopchick, L. A. Frohman, and R. D. Kineman The Growth Hormone (GH)-Axis of GH Receptor/Binding Protein Gene-Disrupted and Metallothionein-Human GH-Releasing Hormone Transgenic Mice: Hypothalamic Neuropeptide and Pituitary Receptor Expression in the Absence and Presence of GH Feedback Endocrinology, March 1, 2001; 142(3): 1117 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Prummel, L. J. S. Brokken, G. Meduri, M. Misrahi, O. Bakker, and W. M. Wiersinga Expression of the Thyroid-Stimulating Hormone Receptor in the Folliculo-Stellate Cells of the Human Anterior Pituitary J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4347 - 4353. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
